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CROSSTALK OF CELL 
METABOLISM AND THE NLR 
INFLAMMASOME
Organisms have developed host defence mechanisms that 
protect from microbial pathogens. The host's immune 
response can also regulate metabolic responses includ-
ing changes in glycolysis, oxidative phosphorylation and 
cholesterol metabolism [1- 3]. These critical biochemical 
reactions play a major role in immune cell function and are 
vital for cell maintenance, energy, proliferation and signal-
ling [4]. Thus, it is not surprising that these metabolic pro-
cesses are regulated and controlled by immune receptors, 
and dysregulation at any of these pathways can have an im-
pact on organismal health and therefore cause a number of 
different autoimmune diseases.
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Abstract
Nucleotide- binding domain and leucine- rich repeat receptor (NLR)- mediated inflamma-
some activation is important in host response to microbes, danger- associated molecu-
lar patterns (DAMPs) and metabolic disease. Some NLRs have been shown to interact 
with distinct cell metabolic pathways and cause negative regulation, tumorigenesis and 
autoimmune disorders, interacting with multiple innate immune receptors to modulate 
disease. NLR activation is therefore crucial in host response and in the regulation of 
metabolic pathways that can trigger a wide range of immunometabolic diseases or syn-
dromes. However, the exact mode by which some of the less well- studied NLR inflam-
masomes are activated, interact with other metabolites and immune receptors, and the 
role they play in the progression of metabolic diseases is still not fully elucidated. In this 
study, we review up- to- date evidence regarding NLR function in metabolic pathways and 
the interplay with other immune receptors involved in GPCR signalling, gut microbiota 
and the complement system, in order to gain a better understanding of its link to disease 
processes.
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Inflammasomes are an essential part of host defence 
and have been also implicated in metabolic regulation 
[5,6]. Inflammasomes are multiprotein complexes that be-
come activated in response to a variety of physiological 
and pathogenic stimuli. Canonical inflammasome assem-
bly through caspase 1 activation is highly regulated and 
two different danger signals are required for its activation, 
priming and activation. Priming is initiated mainly by 
activation of PRRs, including TLR4 and cytokine recep-
tors, leading to nuclear translocation of nuclear factor κB 
(NF- κB) and subsequent upregulation and translation of 
pro- interleukin- 1β (pro- IL- 1β) (pro- IL- 18 is constitutively 
expressed). Inflammasome assembly and activation re-
quire cytosolic sensing of pathogen- associated molecular 
patterns (PAMPS) or danger- associated molecular patterns 
(DAMPS) by a nucleotide- binding domain and leucine- rich 
repeat receptor (NLR) or absent in melanoma 2 (AIM2)- 
like receptors (ALR). NLRs and ALRs engage caspase 1, 
in most cases requiring the recruitment and binding of the 
ASC (apoptotic- speck- containing protein with a CARD), to 
catalyse proteolytic cleavage of pro- IL- 1β and pro- IL- 18, 
as well as gasdermin D (GSDMD) cleavage, forming pores 
on the cell membrane leading to pyroptosis (Figure 1) 
[7,8]. The main NLRs that have been linked with metabolic 
F I G U R E  1  Activation of NLRs, non- canonical and canonical inflammasomes. Structure and activating ligands of canonical NLRP3, 
NLRC4, NLRP1 (human NLRP1 inflammasome contains PYD, mouse NLRP1 does not), NLRP6 and AIM2 inflammasomes, as well as non- 
canonical NLRP3 inflammasome, and NLRC3 and NLRX1, which are non- inflammasome forming NLRs. Human and mouse NLRs and AIM2 
get activated in response to distinct ligands. Double- stranded RNA (dsRNA) is an activator of human NLRP1 while anthrax lethal toxin activates 
murine NLRP1B. NLRC4 inflammasome gets activated by T3SS/T4SS indirectly by detecting flagellin, or directly by detecting the T3SS rod 
protein. Mouse NAIP5 and 6 detect flagellin, mouse NAIP 1 and 2 as well as human NAIP respond to proteins of type III secretion systems (T3SS). 
Upon ligand binding, NAIP and NLRC4 assemble into an oligomerized inflammasome. Among several bacterial ligands of AIM2, Francisella 
tularensis and Listeria monocytogenes act as activators of mouse AIM2 inflammasome. DNA and RNA viruses are ligands to mostly human 
AIM2 inflammasome. Canonical activation of inflammasomes results in oligomerization of ASC into speck complexes, recruiting pro- caspase 
1 leading to self- cleavage and activation of caspase 1. Caspase 1 cleaves pro- IL- 1β (produced by NFκB- induced upregulation) and pro- IL- 18, 
as well as GSDMD cleavage. The N- terminal fragment of GSDMD forms pores on the cell membrane and enables secretion of IL- 1β and IL- 18, 
with subsequent pyroptosis. Non- canonical NLRP3 inflammasome activation occurs via human caspase 4 and 5 or murine caspase 11. Sensing of 
intracellular LPS by pro- caspase 11 leads to caspase 11 activation and subsequent GSDMD cleavage, as well as K+ efflux promoting the activation 
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regulation include pyrin domain- containing protein 1 
(NLRP1), NLRP3, NLRP6, NLRP12, NLR family CARD 
(caspase activation and recruitment) domain- containing 
4 (NLRC4), NAIP (neuronal apoptosis inhibitor protein), 
NLRC3 and NLRX1, and members of the PYHIN family 
include absence in melanoma 2 (AIM2) [6,9].
METABOLIC REGULATION AND 
INFLAMMASOME INTERACTIONS
NLRP3
Activation of the NLRP3 inflammasome can be modulated 
by the metabolic state of a cell and acts as a general sen-
sor of cellular homeostasis. For instance, increased AMP 
leads to inhibition of inflammasome activation by acti-
vating the nutrient sensor AMP- dependent protein kinase 
(AMPK), which causes a metabolic switch from glycolysis 
(and energy- consuming pathways linked to high cellular ac-
tivity) to OXPHOS, which is linked to anti- inflammatory, 
quiescent and contracting cell responses [10]. In addition, 
glycolytic and Krebs cycle enzymes have been reported to 
induce NLRP3 inflammasome activation. The glycolytic 
enzyme pyruvate kinase M2 (PKM2) activates the NLRP3 
inflammasome in macrophages stimulated with LPS via 
hypoxia- inducible factor 1- alpha (HIF1α) regulation, caus-
ing maintained IL- 1β production [11]. Other signals linked 
to cellular stress that activate NLRP3 include ATP influx, 
reactive oxygen species (ROS) and increased concentration 
of intracellular calcium ([Ca2+]i) (Figure 1) as a result of 
ion fluxes or changes in glucose and lipid metabolism [12]. 
Recent studies showing NLRP3 activation by changes in 
lipid metabolism, such as increased endoplasmic reticulum 
cholesterol levels via NPC1, or saturated fatty acids crystal-
lization via lysosomal destabilization, are crucial to provide 
further key roles for inflammasomes in lipid metabolism- 
related diseases [13]. Metabolic regulation of the NLRP3 in-
flammasome has been extensively investigated and is deeply 
described in the following reviews [9,14], the focus here is on 
the less well- studied inflammasomes.
NLRC4
Regulation of the NLRC4 inflammasome has been mainly 
linked to lipid metabolism and acts as a contributor to pathol-
ogy in several immunometabolic diseases. Murine NAIP5 
(NLR family, apoptosis inhibitory protein 5)/NLRC4 inflam-
masome activation by cytosolic delivery of bacterial flagel-
lin has been shown to cause an eicosanoid storm, causing an 
uncontrolled release of signalling lipids such as prostaglan-
dins, leading to inflammation, vascular fluid loss and death 
in mice. This process was dependent on the initial caspase 
1 activation by NAIP5/NLRC4, triggering Ca2+ influx and 
cyclooxygenase 1 stimulation, a crucial enzyme in lipid me-
tabolism responsible for prostaglandin biosynthesis, leading 
to the eicosanoid storm [15].
Importantly, NLRC4 inflammasome activation has 
been involved in several metabolic diseases such as colitis- 
associated tumorigenesis [16], obesity- associated breast 
cancer progression, non- alcoholic steatohepatitis (NASH), 
diabetic nephropathy (DN) and type 1 diabetes (T1D). 
Activated NLRC4 leading to IL- 1β signalling has been re-
ported to contribute to pathology and angiogenesis in obese 
mice with breast cancer via adipocyte- mediated vascular 
endothelial growth factor A (VEGFA) expression [17]. In 
addition, the omega- 3 fatty acid (ω- 3 FA) docosahexaenoic 
acid (DHA), which has a protective effect against NASH, has 
recently been shown to alleviate the palmitate (PA)‐ induced 
inflammatory agents and lipid accumulation via suppression 
of human NLRC4 expression and inhibition of caspase 1 and 
IL- 1β cleavage. NLRC4 knockdown inhibited PA- induced 
inflammation and lipid accumulation, therefore presenting 
DHA as a potential antagonist for NLRC4 to provide benefi-
cial hepatoprotective effects in NASH [18].
NLRC4- driven IL- 1β production has also been shown to 
contribute to pathology in DN, where NLRC4- deficient mice 
showed decreased blood glucose and albumin excretion, to-
gether with preserved renal histology and lower DN progres-
sion [19]. In addition, two recent studies identified certain 
human NLRC4 polymorphisms associated with markers of 
glucose and lipid metabolism: insulin levels and higher tri-
glyceride levels associated with NLRC4 polymorphisms from 
a healthy southern Brazil population [20], and positive rate of 
glutamic acid decarboxylase antibody (GADA) and the onset 
age associated with rs385076 NLRC4 polymorphism in pa-
tients with T1D in a Chinese Han population [21], indicating a 
clear association between NLRC4 and clinical characteristics 
of T1D. Further investigation should focus in the metabolic 
modulators involved in NLRC4 inflammasome contribution to 
ND and possibly T1D. In addition, it would be interesting to 
determine whether similar molecular mechanisms of NLRC4 
leading to eicosanoid storm and inflammation that were ob-
served in mice, such as cyclooxygenase 1 stimulation, are also 
involved in NASH (Table 1).
NLRP1
A wide range of studies has identified the NLRP1 inflamma-
some as a sensor of metabolic stress, leading to IL- 18 pro-
duction. Human NLRP1 gets activated by double- stranded 
RNA (dsRNA) and enteroviral 3C protease [22,23], whereas 
NLRP1B, the murine paralog of NLRP1 that forms an in-
flammasome, is mainly activated in response to anthrax lethal 
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toxin [24,25]. NLRP1 has a protective or worsening effect in 
different immunometabolic diseases [26,27] and can act as 
a sensor of cellular stress, glucose and lipid metabolism. In 
mice deficient in NLRP1B, changes in medium- chain fatty 
acid (MCFA) and short- chain fatty acid (SCFA) metabolism 
have been associated with microbiome dysbiosis and inflam-
matory bowel disease (IBD) [28]. In addition, the ω- 3 FA 
DHA has been shown to inhibit anthrax lethal toxin- induced 
NLRP1B via β- arrestin [29], clearly indicating the modula-
tory role of lipid metabolism in NLRP1B and its protective 
role in maintaining gut homeostasis.
NLRP1B can also act as a sensor of cellular energy stress, 
being activated by the glycolysis inhibitor 2- deoxyglucose 
(2- DG) and the electron transport chain inhibitor sodium 
azide via depletion of cytosolic ATP. Glucose- free media and 
hypoxia, which lower ATP, both activated NLRP1B inflam-
masome transfected in human fibroblasts, and NLRP1B was 
suggested as a direct sensor of ATP levels [30,31]. In addi-
tion, NLRP1 is upregulated during endoplasmic reticulum 
(ER) stress through PERK and IRE1α, as well as ATF4 tran-
scription factor, which is involved in the general integrated 
stress response (ISR) [32].
Interestingly, NLRP1 has been shown to have a protec-
tive role in diabetes. Diabetic kidney disease (DKD) T1D 
patients with rs2670660 and rs11651270 NLRP1 polymor-
phisms (gain- of- function variants) were associated with 
having a decreased risk of developing DKD. Supporting 
these findings, diabetes- associated metabolites (high glu-
cose and glycated albumin) were used to mimic the diabetic 
milieu in monocytes from healthy individuals and were 
found to increase NLRP1 expression [26]. In addition, the 
same polymorphisms have recently been associated with 
lower susceptibility of T1D [33]. The molecular mecha-
nisms by which NLRP1 regulates T1D, however, are still 
unclear and could potentially uncover new therapeutic tar-
gets for this disease.
Several studies have involved NLRP1 having either a 
protective or worsening role in a variety of metabolic dis-
eases. However, the molecular and metabolic mechanisms 
of NLRP1 that regulate these diseases are still unclear. IL- 
18 production by NLRP1B has shown a protective effect in 
obesity and metabolic syndrome in mice [34]. Conversely, 
NLRP1 is known to contribute to pathology in metastatic 
melanoma [35] and diabetic retinopathy, where excessive 
inflammation and high glucose levels seem to promote dis-
ease [27]. Overall, it is clear that NLRP1 inflammasome has 
a crucial role as a sensor of cellular stress, as well as glu-
cose and lipid metabolic perturbation, maintaining cellular 
homeostasis to prevent a wide range of metabolic diseases. 
However, NLRP1 can also lead to uncontrolled inflammation 
contributing to disease; therefore, further investigation into 
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AIM2
The AIM2 inflammasome can be upstream or downstream 
to metabolic regulation, mainly by metabolites and en-
zymes from glucose metabolism. Pyruvate kinase isoform 
M2 (PKM2)- mediated glycolysis, measured by phospho-
enolpyruvate (PEP) and lactate levels, was shown to ac-
tivate pyruvate dehydrogenase kinase 1 (PDK1), which 
inhibits the entry of pyruvate to the TCA cycle, leading 
to phosphorylation of eukaryotic translation initiation fac-
tor 2 alpha kinase 2 (EIF2AK2) and subsequent enhanced 
activation of mouse and human AIM2 inflammasome by 
poly(dA:dT). AIM2 inflammasome contributed to the 
release of IL- 1β, IL- 18 and septic death in mice, which 
was protected by conditional knockout of PKM2, suggest-
ing a novel mechanism of AIM2 regulation by glycolytic 
metabolism and a potential therapeutic strategy to treat 
sepsis [36].
Furthermore, elevated cholesterol in macrophages is 
known to impair mitochondrial metabolism and activate 
murine AIM2 inflammasome via mtDNA as a possible li-
gand. Production of the soluble cholesterol- 25- hydroxylase 
(Ch25 h)- induced 25- HC (Ch25h produces 25- HC from 
cholesterol) by macrophages was reported to inhibit 
AIM2 inflammasome via suppression of sterol regulatory 
element- binding protein (SREBP2) activation and choles-
terol biosynthesis, resulting in mitochondrial integrity and 
homeostasis [37].
AIM2 regulation has directly been involved with cer-
tain autoimmune diseases, mostly mediated by signalling 
events linked to glucose metabolism. A study using sir-
tuin 1 (SIRT1) knockdown showed that SIRT1  has been 
shown to induce metabolic reprogramming by increasing 
mitochondrial respiration and repress the NF- κB- driven 
transcription of AIM2, contributing to cervical cancer pa-
thology in patients [38]. In addition, deletion of AIM2 in 
mice results in elevated levels of fasting glucose and insu-
lin, leading to white adipose tissue inflammation and obe-
sity via the IFN activated gene Ifi202b [39]. In contrast, 
AIM2 activation by high glucose in rats has recently been 
shown to contribute to pathology in diabetic cardiomyop-
athy via ROS production and the GSDMD pathway [40]. 
Overall, increased glycolysis and disruption in TCA cycle 
and mitochondrial dysfunction have generally been impli-
cated in the activation of AIM2 inflammasome across dif-
ferent studies. It would be interesting to determine whether 
25- HC modulation of this inflammasome is involved in 
diseases where lipid metabolism is disrupted, as well as the 
involvement of other lipid metabolites. In addition, further 
research considering the SIRT1- AIM2 axis as a target for 
cervical cancer will be crucial for the development of new 
therapies.
Non- canonical caspase 11 inflammasome
A recent mouse study identified a mechanism of metabolic 
regulation of the caspase 11 inflammasome by regulation of 
cAMP, which promotes PKA leading to caspase 11 inflam-
masome inhibition. L- adrenaline- induced cAMP via the en-
zyme ADCY4 showed inhibition of cytosolic LPS- induced 
caspase 11 inflammasome pathway and consequent pyropto-
sis in macrophages, and presented this novel interaction with 
caspase 11 inflammasome as a potential therapeutic target 
in sepsis [41]. Interestingly, the cAMP- PKA axis leading 
to inhibition of inflammasome and pyroptosis has also been 
described in several studies involving the canonical NLRP3 
inflammasome [42,43], given its contributing role in chronic 
inflammatory diseases, it would be interesting to explore fur-
ther the cAMP regulation of this inflammasome in sepsis.
NLRC3
NLRC3 whose functions are mostly undiscovered as com-
pared to other NLRs, has been identified as a negative regula-
tor of innate immunity and inflammatory responses [44,45]. 
NLRC3 does not form an inflammasome complex and was 
shown to inhibit LPS- induced Toll- like receptor (TLR) 
signalling by inhibiting the adaptor protein TNF receptor- 
associated factor 6 (TRAF6) [46]. Furthermore, NLRC3 
blocks activation of the PI3K- dependent Akt kinase and in-
hibits mTOR pathways in colon epithelial cells [45].
Interestingly, NLRC3 plays a major role in T- cell metabo-
lism. Aerobic glycolysis is a metabolic hallmark of activated 
T cells and Th1 cell differentiation [47]. NLRC3 acts as a 
brake, diminishing metabolic pathways to attenuate T- cell 
activation in a NF- κB- dependent manner. NLRC3 deficiency 
in mice increases oxidative phosphorylation and glycolytic 
capacity, driving Th1 and Th17 cell differentiation, prolif-
eration and IFN- γ, IL- 2, TNF and IL- 17 production, thus 
leading to unrestrained generation of activated CD4+ T cells 
with maximal glycolytic and mitochondrial metabolism 
[48], which could lead to autoimmune disease progression. 
Profiling of T cells from patients with multiple sclerosis 
(MS) has reported increased glycolysis and mitochondrial ac-
tivity [49]. Therefore, it could be possible that a deficiency in 
NLRC3 expression within the human population could pre-
dispose individuals with low CD4+ T- cell NLRC3 expression 
to develop multiple sclerosis (MS) or MS- related disorders.
NLRX1
NLRX1, an enigmatic modulator of immune function, is part 
of an NLR family subgroup which are non- inflammasome` 
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forming and regulate the inflammation associated with other 
PRRs activation. The location and trafficking of NLRX1 is 
debated but it is known to negatively regulate type I inter-
feron, IL- 6, NF- κB signalling and to induce ROS production, 
activating the JNK pathway leading to apoptosis [50- 54].
Loss of function of NLRX1 has been linked with a variety 
of autoimmune diseases, such as cancer, colitis, inflamma-
tory bowel disease and CNS inflammation [55]. In human 
breast cancer cells, NLRX1 expression is increased and, in 
the presence of TNF, helps maintenance of mitochondrial 
metabolism- lysosomal crosstalk to regulate invasion and me-
tastasis capability. NLRX1 deletion results in lysosomal dys-
function and decreased turnover of damaged mitochondria 
via mitophagy, leading to a reduction of OXPHOS- mediated 
cell proliferation and migration ability [56]. In mouse T cells, 
loss of NLRX1 mediated increased lactate dehydrogenase 
activity, suggesting a preference for aerobic glycolysis, and 
a greater ability to proliferate and differentiate into a pro- 
inflammatory phenotype, combined with a reduced sensi-
tivity to immune checkpoint pathways. Interestingly, in the 
same study NLRX1 showed a protective effect against colitis, 
where rag2−/− mice (an adoptive- transfer model of colitis) 
receiving nlrx1−/− naive or effector T cells, showed increased 
disease activity [57]. Another study showed that NLRX1 de-
letion in colitis mice drives changes in gut– microbiome in-
teractions exacerbating disease; however, restoration of WT 
glutamine metabolic profiles via glutamine supplementation 
abrogated effects in microbiome, inflammation and disease 
F I G U R E  2  Metabolic regulators of the inflammasome in the crossroads with: GPCR signalling, host– microbiota communication and the 
complement system. (A) GPCRs that activate or inhibit NLRP3 inflammasome by metabolites. GPR43 and/or GPR109A act as SCFA (mainly 
acetate) receptors to induce NLRP3 inflammasome activation via K+ efflux, increased Ca2+ mobilization and membrane hyperpolarization in 
gut epithelial cells, or to repress NLRP3 inflammasome activation via decreased Ca2+ mobilization and activation of sAC and PKA in BMDMs. 
GPR120, receptor of the ω- 3 FA DHA, inhibits NLRP3 activation through suppression of NF- κB and binding of β- arrestin 2 (Arrβ2) to NLRP3, 
impeding its assembly. BHB inhibits NLRP3 activation via an undefined Gαi- coupled GPCR. TGR5 and EP4, receptors of bile acids (LCA) and 
PGE2, respectively, both inhibit NLRP3 via cAMP- PKA signalling, causing NLRP3 phosphorylation. PGE2 can also promote NLRP3 priming via 
EP4- cAMP- PKA signalling leading to NF- κB activation in BMDMs. The bile acid CDCA can bind TRG5 leading to NLRP3 activation through 
K+ efflux and ROS production. (B) Inflammasome activation in the gut by metabolites leads to IL- 18 release which promotes AMP production 
and secretion by nearby cells, controlling the gut microbial composition. Upon dysbiosis induction, histamine and spermine inhibit NLRP6- 
dependent IL- 18 and AMP, supporting the dysbiotic microbiota. Taurine reduces spermine and histamine levels and induces IL- 18 secretion and 
improved microbiota composition. H2S inhibits NLRP3 inflammasome and IL- 1β secretion in DSS- induced colitis colons via reduced ROS and 
Nrf2 activation.The bile acid analogue BAA473 activates pyrin inflammasome in intestinal epithelial cells leading to IL- 18 secretion. (C) The 
complement system activates NLRP3 inflammasome via metabolic changes. Activation of C3aR drives ATP efflux from the cytosol and ERK1/2 
phosphorylation. ATP efflux triggered by C3a activates P2X7, leading to NLRP3 activation. C5a binding to C5aR1 triggers NLRP3 inflammasome 
priming and activation via ROS production, lysosomal damage and cathepsin B activity. CD46- CYT- 1 upregulated by TCR stimulation through 
autocrine C3b production drives upregulation of LAT1 and GLUT1, which mediate nutrient influx into the cell, as well as LAMTOR5. LAMTOR5 
drives mTORC1 activation (a known NLRP3 inflammasome activator) leading to increased glycolysis and Th1 cell induction. CD46- CYT- 1 
signalling also primes NLRP3 inflammasome by upregulating IL- 1β and NLRP3. Membrane attack complex deposition drives NLRP3 activation 
in human lung epithelial cells via Ca2+ influx, increased [Ca2+]i in the cytosol and endoplasmic reticulum (ER) stores, subsequent mitochondrial 
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severity [58]. In addition, a novel orally active, gut- restricted 
drug named NX- 13 has been shown to activate mouse 
NLRX1 and alleviate disease severity in IBD mouse mod-
els, as well as increased OXPHOS, decreased differentiation 
into Th1 and Th17 subsets and decreased ROS and NF- κB 
activation in naïve CD4+ T cells. In addition, NX- 13 activa-
tion of NLRX1 also showed resistance to oxidative stress and 
inflammation in human primary cells from ulcerative colitis 
patients, therefore becoming a promising NLRX1 agonist for 
treating IBD [59- 61].
Finally, NLRX1 has been identified as a regulator of 
glutamate homeostasis in the CNS. Astrocyte dysfunction 
leading to accumulation of extracellular glutamate and lack 
of NLRX1 is known to be associated with CNS trauma and 
excessive inflammation [62- 64]. Using NLRX1- depleted 
mice, NLRX1 was reported to potentiate mitochondrial 
function causing increased astrocytic glutamate uptake, as 
well as inhibition of Ca2+- mediated glutamate exocytosis, 
leading to repression of glutamate release from astrocytes, 
suggesting a protective role of NLRX1 in CNS inflamma-
tion [65]. Overall, NLRX1 has been described to act as a 
brake in inflammation and negative regulator of pathology, 
playing a key role in the regulation of immunometabolism 
with links to disease. The emergence of NLRX1 agonists 
such as NX- 13 show the potential in targeting NLRX1 to 
modulate immunometabolic function in diease, and future 




INTERACTIONS AND OTHER 
IMMUNE PATHWAYS
GPCR signalling
G protein- coupled receptors (GPCRs) are an extensive 
family of membrane receptors known to share seven- 
transmembrane α- helix domains, with an intracellular C ter-
minus and a large extracellular N terminus. Generally, the 
extracellular region senses extracellular ligands such as ions, 
metabolites, chemokines and temperature, causing confor-
mational changes in the receptor and subsequent transduction 
of the signal into intracellular responses, activating further 
downstream signalling pathways. Canonical GPCRs are clas-
sically modulated by the intracellular region ligands: G pro-
teins, which activate downstream signalling, or β- arrestins, 
which can control excessive activation [66,67]. GPCRs are 
the most common class of targets for therapeutic drugs (~35% 
of approved drugs) due to their relevance in several human 
diseases, restricted expression and structure. However, only 
about 16% of the ~800 different GPCRs have been targeted 
for therapeutic drugs, leaving a substantial number of dis-
tinct GPCRs to be explored as potential therapeutic targets 
[68,69].
Activation of inflammasomes, mainly NLRP3, can be 
modulated via GPCRs interacting with different metabolites, 
ions, neurotransmitters and hormones, indicating crosstalk 
between metabolism, GPCR signalling and inflammasomes. 
Metabolites and metabolic proteins involved in such process 
include ω- 3 FAs, cyclic adenosine monophosphate (cAMP), 
β- hydroxybutyrate (BHB), bile acids, prostaglandin E2 
(PGE2) and SCFAs such as acetate (Figure 2).
SCFAs are derived from commensal anaerobic bacterial 
fermentation of dietary fibre and are known to play a cru-
cial role in gut homeostasis and inflammation. SCFA ace-
tate binding to metabolite- sensing receptors GPR43 and/
or GPCR109A has been shown to mediate a protective 
effect against colitis and drive activation of NLRP3 inflam-
masome in epithelial cells, showing caspase 1 activation 
and secretion of IL- 18. Acetate led to GPR43- dependent 
inflammasome activation through K+  efflux, Ca2+ mobili-
zation and downstream hyperpolarization [70]. Conversely, 
acetate interacting with GPR43 in bone marrow- derived 
macrophages (BMDMs) has recently been described as a 
suppressor of NLRP3 inflammasome via a Ca2+- dependent 
mechanism, leading to decreased Ca2+ mobilization. The 
mechanism also involved adenylyl cyclase (sAC)- PKA sig-
nalling leading to NLRP3 ubiquitination and autophagy. In 
addition, the study showed that acetate had a protective effect 
on NLRP3- dependent peritonitis in vivo [71].
Certain GPCRs can have a dual effect on regulating the in-
flammasome in different situations and inflammatory states; 
therefore, further research is crucial to better understand their 
mechanisms and establish more GPCRs as new therapeutic 
targets. Another example of that is the PGE2 receptor 4 (EP4) 
and the bile acids active membrane receptor TGR5, which are 
known to inhibit or activate NLRP3. EP4 binding to PGE2 
can inhibit or activate priming of NLRP3 via cAMP in-
crease and subsequent PKA activation: in HEK cells, cAMP 
leads to phosphorylation of human NLRP3 on Ser295 and 
PKA decreases its ATPase function causing NLRP3 inhibi-
tion, whereas in BMDMs, PGE2 promotes NLRP3 priming 
through the EP4- cAMP- PKA mechanism leading to NF- κB 
activation [43,72]. Interestingly, TGR5 binding to lithocholic 
acid (LCA) can suppress NLRP3 in a similar mechanism 
which is also cAMP- PKA dependent, where PKA leads to 
NLRP3 phosphorylation on mouse Ser291 (corresponding to 
human S295), causing ubiquitination of NLRP3. The same 
study showed prevention of high- fat diet- induced insulin re-
sistance downstream of TGR5- NLRP3 inhibition axis [42]. 
Conversely, TGR5 binding to the major bile acid involved 
in cholestatic liver injury, chenodeoxycholic acid (CDCA), 
leads to activation of NLRP3 by an independent cAMP- PKA 
mechanism, where ROS production, K+ efflux and c- Jun 
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N- terminal kinase pathways have been involved [73]. It is 
important to note that CDCA binding to TGR5 has been re-
ported to both activate and inhibit NLRP3- mediated caspase 
1 activation and IL- 1β secretion in BMDMs through different 
mechanisms, the biological basis of these discrepancies has 
not been elucidated and therefore more research is needed to 
clarify the CDCA- TGR5- inflammasome axis [42,73].
Metabolites that have been reported to only in-
hibit the inflammasome via GPCRs are ω- 3 FAs and β- 
hydroxybutyrate. The ω- 3 FA docosahexaenoic acid (DHA) 
interacting with its receptor GPR120 was shown to inhibit 
inflammasome priming and activation, first through sup-
pression of NF- κB and then inhibiting IL- 1β release via in-
creased autophagy. Interestingly, not only NLRP3 but also 
NAIP5/NLRC4 and AIM2 inflammasomes were involved 
in this process. In addition, DHA mediated β- arrestin 2 re-
cruitment to GPR120, leading to a β- arrestin 2- dependent 
reduction of inflammasome activation [74]. Finally, while 
the ketone body BHB was found to inhibit NLRP3 inde-
pendently of GPCRs in macrophages and neutrophils, it has 
recently been reported that in C6 glioma cells, BHB can 
inhibit NLRP3 through a Gαi- coupled GPCR, whether that 
is the BHB Gαi- coupled receptor GPR109A or not remains 
to be explored [75].
It is clear that certain metabolism– inflammasome inter-
actions with GPCR signalling are still controversial, this is 
especially apparent in the case of SCFAs having opposite 
roles as modulators of NLRP3 inflammasome in colitis and 
peritonitis, which could be attributed to the fact that stud-
ies were performed in different cell types and experimental 
conditions. Thus, further research should focus on the up-
stream NLRP3 activation mechanisms in disease, as well as 
understanding how GPCR- driven cAMP production inhibits 
NLRP3, or whether other inflammasomes other than NLRP3 
are involved in GPCR signalling.
Host– Microbiota communication
The gut microbiota is known to communicate with the 
host having a commensal interaction, where microbes and 
their derived metabolites resident in the gut are able to 
sense changes in the microbiota and act as signals to regu-
late a variety of signalling pathways including host PRRs, 
such as inflammasomes. The inflammasomes regulated by 
microbiota- associated metabolites have mainly been NLRP6, 
NLRP3 and pyrin (Figure 2). Inflammasome activation at a 
basal level and production of IL- 18 in the gut are crucial to 
maintain homeostasis of the intestinal microbiome; however, 
dysregulation of inflammasome activation caused by cer-
tain host and gut- derived metabolites can lead to dysbiosis 
[76,77]. Dysregulation of the microbiota homeostasis can 
alter the intestinal barrier's function with unwanted leakage 
of pro- inflammatory signals, as well as alteration of many 
metabolic products contributing to dysbiosis- associated in-
testinal carcinogenesis and non- alcoholic fatty acid disease 
(NAFLD) [78,79].
Given the high expression of NLRP6 in the intestine, it 
is not unexpected that its ligands are mostly derived from 
bacterial components in the gut. Expression of NLRP6 in 
gut epithelial cells has been shown to regulate the intes-
tinal microbiota and mucus secretion [80]. Furthermore, 
a metabolomics– metagenomics analysis of caecal con-
tent identified microbiota- modulated metabolites as co- 
modulators of NLRP6 inflammasome activation, with 
downstream epithelial IL- 18- induced antimicrobial peptide 
(AMP) production, driving stability of the intestinal micro-
bial community. In vitro and in vivo mice studies showed 
that upon dysbiosis induction, the metabolites histamine 
and spermine inhibited NLRP6 inflammasome- dependent 
IL- 18 production, supporting the dysbiotic microbiota. 
Administration of taurine showed reduced spermine and 
histamine levels and induced IL- 18 production, improved 
microbiota composition and had a protective effect against 
colitis via NLRP6 inflammasome [76]. Interestingly, a re-
cent study showed improvement of gut permeability and 
reduction of intestinal inflammation after reactivating 
NLRP6 through Roux- en- Y gastric bypass (RYGB) surgery 
in obese rats, housed in a specific pathogen- free facility. 
After RYGB, increased taurine positively affected NLRP6 
expression [81].
In contrast, studies conducted in germ- free facilities con-
tradicted the aforementioned studies and observed no impact 
of NLRP6 in gut microbiota composition, attributing this re-
sult to the fact that they used littermate- controlled WT and 
NLRP6- deficient mice to minimize non- genetic confounders, 
allowing them to shape their gut microbiota naturally after 
birth. Such studies alleged that the results obtained by pre-
vious studies showing the opposite effect were not obtained 
from littermate animals; therefore, it was possible that the 
dysbiosis observed in the NLRP6- deficient mice was geno-
type independent and acquired stochastically [82,83].
A recent study identified a secondary metabolite of 
flavonoids and a common constituent of the human diet, 
apigenin, as a regulator of gut microbiota via NLPR6. 
Apigenin showed a protective effect against colitis in 
mice via NLRP6 signalling, which still happened in the 
absence of caspase 1/11 or Asc, suggesting that an al-
ternative mechanism to the classical inflammasome 
pathways was involved. Mice showed protection against 
colitis when cohoused with apigenin- treated mice, 
whereas NLRP6- deficient mice lost the protective effect 
[84]. Thus, the role of NLRP6 inflammasome as a reg-
ulator of intestinal microbiota is still controversial and 
further research, possibly in human studies, is needed to 
confirm this role.
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Activation of NLRP3 inflammasome in the colon has 
been shown to have both protective and detrimental effects in 
different colitis studies. NLRP3 deficiencies showed either 
defects in intestinal mucosa repairing, exacerbating disease, 
or decreased levels of secreted IL- 1β and autoinflammation, 
reducing disease severity [70,85- 87]. In an aforementioned 
study, bacterial SCFAs metabolites showed steady- state 
NLRP3 inflammasome activation and IL- 18 production 
in epithelial cells, leading to regulation of the microbiome 
composition, reduction of inflammatory responses and a pro-
tective effect against colitis [70]. Conversely, the bacterial 
metabolite hydrogen sulphide (H2S) has been shown to in-
hibit NLRP3 inflammasome and IL- 1β secretion in BMDMs 
and in dextran sulphate sodium (DSS)- induced colitis colons 
via reduced ROS and Nrf2 activation. In addition, H2S atten-
uated the severity of mouse colitis by NLRP3 inflammasome 
inhibition [88]. Different levels of tissue injury and inflam-
mation caused by intestinal NLRP3 can determine its protec-
tive or detrimental function in the gut, which can also depend 
on the different experimental conditions between studies 
[89].
Interestingly, a screen for microbiome metabolites that 
may function as inflammasome activators recently identified 
BAA473, a bile acid analogue, as a pyrin inflammasome acti-
vator leading to IL- 18 secretion in human intestinal epithelial 
and myeloid cells. Given the crucial role of IL- 18 in the gut, 
the study suggests that microbiota- mediated bile acid con-
version might modulate intestinal homeostasis via the pyrin 
inflammasome pathway [90].
Finally, NLRP12 has been reported to have a protective 
role in IBD patients and act as a regulator of the colonic mi-
crobiota and suppressor of inflammation to microbial ligands. 
NLRP12 deficiencies in mice lead to IL- 6 and TNF- driven 
colonic inflammation and dysbiosis via an inflammasome- 
independent pathway [91]. However, whether there are any 
bacterial metabolites that regulate NLRP12 and its func-
tions in the gut remain to be explored. Overall, the contro-
versial evidence regarding the involvement of NLRP6 and 
its microbiota- derived metabolites as regulators of gut ho-
meostasis, as well as the different roles of NLRP3 against 
colitis, which possibly lays in different cell types and grades 
of inflammasome activation, indicates the need for further 
research in human disease settings and into the downstream 
mechanisms that control these effects.
The complement system
In recent decades, it has become apparent that the comple-
ment system and inflammasomes are not only pathogen 
sensors, but also systems that can recognize cell metabolic 
changes and induce reactive responses, for instance, to sup-
port cell activation or to maintain cell homeostasis. Several 
complement receptors and regulators have been presented as 
critical signals for NLRP3 inflammasome activation, either 
linked with signals coming from RLR or TLR activation, or 
independently [92]. This process can occur through meta-
bolic changes being upstream or downstream to complement, 
leading to inflammasome activation (Figure 2).
Activation of the complement anaphylatoxin receptor 
C3aR in myeloid cells results in NLRP3 inflammasome 
activation. This process has been reported to occur in the 
presence of LPS and TLR4 activation through increased 
ATP efflux from the cytosol and ERK1/2 phosphorylation. 
ATP efflux triggered by C3a resulted in P2X purinoceptor 7 
(P2X7) activation, leading to inflammasome activation [89]. 
Interestingly, an ATP- inflammasome- complement axis has 
recently been proposed, where complement is activated by 
DAMPs released by inflammasome activation, promoting 
sterile brain inflammation [93].
C5a generation driven by cholesterol and acid uric crys-
tals has also been shown to act as a trigger for the NLRP3 
inflammasome. Abnormally high concentrations of the me-
tabolite cholesterol, which can be driven by defects in cho-
lesterol metabolism and homeostasis, precipitate to form 
cholesterol crystals (CC) driving inflammation and contrib-
uting to pathogenesis in atherosclerosis [94]. A study showed 
that CC activate complement and that the resulting C5a gen-
erated, combined with TNF- α, triggered ROS and priming 
of the inflammasome [95], suggesting complement inhibition 
as a potential therapeutic target for atherosclerosis treatment. 
Furthermore, studies in which inflammation was induced by 
the crystalized metabolite uric acid in monocytes as a model 
of gout disease have shown that C5aR1 triggers priming and 
activation of the inflammasome via lysosomal damage and 
cathepsin B activity [96]. This role for C5a was confirmed by 
other studies using neutrophils in a mouse peritonitis model 
[97].
Complement can not only regulate metabolic changes 
at a systemic level [98], but also at an intracellular level. 
Autocrine complement activity has been shown to induce 
metabolic reprogramming leading to T- cell activation and 
inflammasome activation [99,100]. Human CD4+ T cells 
express CD46 in two different isoforms based on their 
cytoplasmic tails, known as CYT- 1 and CYT- 2. CD46- 
CYT- 1 is upregulated by T- cell receptor (TCR) stimula-
tion via autocrine C3b production, leading to increased 
expression of the amino acid and glucose transporters 
LAT1 and GLUT1, as well as MAPK and MTOR activator 
5 (LAMTOR5), leading to Th1 cell induction. LAT1 and 
GLUT1 mediate nutrient influx, while LAMTOR5 drives 
mTORC1 activation and glycolysis, a metabolic hallmark 
in activated T cells and known NLRP3 inflammasome ac-
tivator [92]. Alternatively, CD46- CYT- 2 is expressed in 
resting and contracting T- cells, where CD46- CYT- 2 me-
diates a switch from glycolysis to OXPHOS metabolism 
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[99]. Interestingly, CD46 (which binds C3b) stimulation 
in activated CD4+T cells was found to simultaneously 
upregulate IL- 1β and NLRP3 gene expression to prime 
the NLRP3 inflammasome, as well as increase intracel-
lular generation of C5a and activation of C5aR1, which 
led to increased ROS production and subsequent NLRP3 
inflammasome activation and Th1 cell induction [100]. 
Dysregulation of C3 and CD46 in CD4+ T cells has been 
reported to contribute to Th1- mediated autoimmune dis-
eases [101- 103]. Furthermore, cytotoxic CD8+ T cells 
have recently been involved in the CD46 regulator costim-
ulation signalling, leading to increased fatty acid synthesis 
and nutrient influx which promote optimal cell activity. 
However, this process was not linked with the canonical 
NLRP3 signalling [104].
Finally, studies in dendritic cells, C6- deficient mice [105] 
or in human lung epithelial cells have elucidated that sublytic 
membrane attack complex (MAC) activates NLRP3 inflam-
masome via Ca2+ influx, subsequent mitochondrial [Ca2+]i 
uptake and alteration of mitochondrial membrane potential 
[106]. Interestingly, sublytic MAC and increased glycolysis 
have been implicated in rheumatoid arthritis, contributing to 
inflammation [107,108]. Given that MAC is an inflammatory 
trigger and such stimuli have been implicated in the modula-
tion of immunometabolic responses, perturbations in cellular 
metabolism downstream of sublytic MAC might be involved 
in this process. In conclusion, a functional complement– 
metabolism– inflammasome axis has been demonstrated 
particularly in T cells (CD46- C3b and C5aR1- ROS interac-
tions). More complement components such as MAC, as well 
as other cell types are likely to be involved in this axis in 
the future, providing potential novel therapeutic targets in the 
treatment of autoimmune diseases.
CONCLUSIONS AND FUTURE 
PERSPECTIVES
Growing evidence on modulation of inflammasome activa-
tion by metabolic changes has become apparent in the re-
cent years not only for NLRP3, but also for NLRC4, NLRP1, 
AIM2, NLRP6, NLRP12, pyrin, NLRC3, NLRX1 and non- 
canonical caspase 11 inflammasome. Metabolic control of 
these inflammasomes and non- inflammasome forming NLRs 
implicates a variety of perturbations in the glycolytic path-
way, mitochondrial and lipid metabolism, which has been 
linked to several autoimmune and metabolic diseases, such as 
obesity, diabetes and cancer. The downstream mechanisms of 
the metabolic perturbations that directly regulate the inflam-
masome, however, remain unclear, where some independ-
ent mechanisms have been proposed but not always linked 
to each other. Whether such mechanisms interact with each 
other in a common signalling cascade or distinct pathways 
needs to be understood. Furthermore, novel links between 
inflammasomes and metabolic diseases are recently emerg-
ing, such as NLRP1 and NLRC4’s involvement in T1D and 
diabetic complications, which have been linked to certain 
metabolic markers [21,26]. Elucidation of the mechanism of 
action between the metabolic alterations and inflammasomes 
linked to disease will be crucial to allow development of new 
therapeutic targets.
There is contradictory evidence regarding certain 
metabolism– inflammasome interactions and whether they 
have a protective or worsening effect in disease. SCFAs in-
teracting with GPCR signalling have been reported to both 
activate and inhibit NLRP3 through different mechanisms, 
leading to a protective or detrimental role in colitis/perito-
nitis [70,71]. The fact that metabolites often interact with 
Gs- coupled GPCR signalling to regulate the inflammasome 
indicates potential development of new GPCR- targeted treat-
ments for inflammasome- driven diseases. However, more 
research is needed to understand GPCR regulation of the 
upstream NLRP3 activation mechanisms, as well as how 
GPCR- driven cAMP production inhibits NLRP3, whether 
other inflammasomes other than NLRP3 are involved or how 
to specifically modulate inflammasome activation by target-
ing GPCRs.
NLRP3 and NLRP6 are the main gut inflammasomes, 
NLRP3 and arguably NLRP6, seem to be regulated by the 
metabolic outputs of gut microbiota and have a crucial in-
volvement in DSS- colitis. The recent finding about in-
testinal pyrin inflammasome being activated by bile acids 
presents pyrin as an emerging metabolic sensor in the gut 
[90]. Its upstream mechanisms, role in gut microbiota and 
gut- related diseases, however, remain unclear and need to be 
understood. In addition, gut microbiota activating intestinal 
NLRP3 inflammasome is known to aggravate progression 
of CNS diseases such as AD and has been described as the 
microbiota- gut- brain axis [109- 112]. Whether certain gut 
metabolites (SCFA catabolism [109]) have a role in NLRP3 
activation in CNS diseases should be investigated. Finally, 
the complement– metabolism– inflammasome axis has been 
well described for the NLRP3 inflammasome mainly in T 
cells. More research is needed to unveil whether other in-
flammasomes are involved in this process, as well as other 
primary cells and tissues. Equally important will be to better 
understand if other complement components are involved, 
i.e. further elucidation of the role of MAC complex in this 
axis, and their downstream metabolic mechanisms leading to 
inflammasome activation.
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